LAB Research, a Canadian-based global non-clinical contract research organisation, is set to provide its full suite of services to a Japanese pharmaceutical company, under a preferred provider agreement (PPA) signed between the companies.
Additionally, LAB Research Canada is expected to provide program management resources, annual volume discounts, preferential scheduling and reporting timelines and other operational advantages.
Luc Mainville, president and CEO of LAB Research, said: "The agreement also validates our strategy of developing closer relationships with an increased number of pharmaceuticals that value the quality of our work and our scientific contribution to their research and development program.
"As pharmaceutical companies continue to outsource more and more of their toxicology requirements, this agreement testifies of our ability to participate in the consolidation of business relationships currently taking place in our industry.
"Our ability to pre-qualify our sites to offer services to the pharmaceutical market has translated in a robust increased in activity at each of our sites."